- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03058601
Outcomes in UK ACS Patients Prescribed Ticagrelor
Health Outcomes of Patients With Acute Coronary Syndromes Prescribed Ticagrelor in UK Primary Care: a Retrospective Cohort Study
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.
The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Luton, Verenigd Koninkrijk
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015
- At least 12 months history in database prior to first ticagrelor prescription
- Linkage to Hospital Episode Statistics (HES)
- Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date
Exclusion Criteria:
Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tijdsspanne: From index date up to 12 months
|
From index date up to 12 months
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- D5130R00027
- EUPAS17107 (Register-ID: ENCePP)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Acute kransslagader syndroom
-
Lawson Health Research InstituteVoltooidArteriosclerose van Arterial Coronary Artery Bypass GraftCanada
-
Deutsches Herzzentrum MuenchenVoltooidArteriosclerose van Arterial Coronary Artery Bypass GraftDuitsland